Blue Water Life Science Advisors, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Blue Water Life Science Advisors, LP reported 10 stock positions worth $124.7 million. Its top holding was 10X Genomics Class A (TXG) at 18.6% of the portfolio, followed by Guardant Health (GH, 17.9%) and Caredx (CDNA, 13.0%). Compared with Q4 2025, it opened 2 new positions, sold out of 1, added to 3 and reduced 4. The biggest buy was a new position in 10X Genomics Class A (TXG) and the biggest sale Natera (NTRA, shares −68%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001789778
- Portfolio Value
- $124.7M (Q1 2026)
- SEC Filing
- 0001420506-26-001003 ↗ filed May 14, 2026
Holdings Value
Holdings 10 stocks · $124.7M
| TXG 10X Genomics Inc. Class A | 18.56% | 1,090,000 | $23.1M | New |
| GH Guardant Health Inc. | 17.94% | 242,247 | $22.4M | Reduce -31.8% |
| CDNA Caredx Inc. | 13.02% | 935,000 | $16.2M | Add +83.3% |
| ADPT Adaptive Biotechnologies | 11.24% | 1,010,145 | $14.0M | Reduce -42.8% |
| TWST Twist Bioscience Corp. | 10.52% | 276,000 | $13.1M | Reduce -27.9% |
| PSNL Personalis Inc. | 8.56% | 1,676,300 | $10.7M | No change |
| NTRA Natera Inc. | 7.18% | 44,794 | $9.0M | Reduce -68.3% |
| QTRX Quanterix Corp. | 6.05% | 2,142,147 | $7.5M | Add +2.4% |
| TEM Tempus AI Inc. Class A | 5.67% | 156,412 | $7.1M | Add +81.0% |
| BLLN Billiontoone Inc. Class A | 1.27% | 20,000 | $1.6M | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $158.8M | CDNA, TXG, PSNL, ADPT, GH |
| Q1 2026 | 10 | $124.7M | TXG, GH, CDNA, ADPT, TWST |
| Q4 2025 | 9 | $159.3M | GH, NTRA, ADPT, PSNL, QTRX |
| Q3 2025 | 7 | $109.6M | ADPT, GH, NTRA, PSNL, CDNA |
| Q2 2025 | 8 | $126.3M | NTRA, ADPT, GH, CDNA, TXG |
| Q1 2025 | 7 | $100.9M | GH, NTRA, ADPT, CDNA, AKYA |
| Q4 2024 | 9 | $112.9M | NTRA, GH, CDNA, ADPT, AKYA |
| Q3 2024 | 8 | $113.7M | NTRA, CDNA, EXAS, AKYA, ADPT |
| Q2 2024 | 8 | $102.8M | NTRA, GH, AKYA, CDNA, TXG |
| Q1 2024 | 8 | $106.3M | NTRA, AKYA, GH, TXG, QTRX |